Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience

Bonifati, C.; Morrone, Andrea; Cristaudo, Antonio; Graceffa, Dario

doi:10.1111/dth.14584

Cited by 31 publications

(59 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the population was limited to a small-scale and the Western population. 15 – 18 The patients previously treated with biologics in this study were less likely to achieve PASI 75 than biologic-naïve patients. Furthermore, lower PASI 75 response rate to guselkumab was noted as the number of previous biologics used increased.…”

Section: Discussionmentioning

confidence: 84%

“…These studies are mostly short-term, have small population sizes, and comprise non-Asian populations. 8 , 15 – 19 , 21 PASI 75 and PASI 90 responses to guselkumab in two short-term (16 weeks) multicentre real-life studies showed that 82.1% and 72.2% of patients achieved PASI 75, whereas 55.4% and 50.6% achieved PASI 90 at week 16. 8 , 15 Our patients responded to guselkumab even worse compared with those in other real-life studies.…”

Section: Discussionmentioning

confidence: 99%

“…15,16,19,21 Predictors of a PASI response to guselkumab available from real-life studies are relatively lacking and inconsistent. [15][16][17][18] The efficacy of biologics was lower in patients with higher BW, which might be due to the increased volume of drug distribution and low level of drug concentration. 23 The efficacy was maintained in weight-based dosage of biologics such as infliximab, even with increasing weight.…”

Section: Discussionmentioning

confidence: 99%

“… 15 , 16 , 19 , 21 Predictors of a PASI response to guselkumab available from real-life studies are relatively lacking and inconsistent. 15 – 18 …”

Section: Discussionmentioning

confidence: 99%

“…Real-life studies on the use of guselkumab in the treatment of psoriasis are relatively few compared with those of other biologics. These studies are mostly shortterm, have small population sizes, and comprise non-Asian populations 8,[15][16][17][18][19]21. PASI 75 and PASI 90 responses to guselkumab in two shortterm (16 weeks) multicentre real-life studies showed that 82.1% and 72.2% of patients achieved PASI 75, whereas 55.4% and 50.6% achieved PASI 90 at week 16.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

Hung

Lin

Chiu

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Background: Real-life data on patients with psoriasis treated with guselkumab are few and are needed to compare with trial-based data. We investigated the effect of clinical factors on real-world effectiveness of guselkumab. Methods: This multicentre study retrospectively included 135 patients with psoriasis treated with guselkumab from June 2018 until November 2020. Effectiveness was assessed using the degree of improvement in the Psoriasis Area and Severity Index (PASI) scores at baseline and after 4, 12, 20, 28, and 36 weeks. Predictors of effectiveness were also evaluated. Results: At week 36, 67% of the patients achieved PASI 75. Multivariate logistic regression analysis revealed that heavier patients were less likely to achieve PASI 75 at week 4 than patients with lower body weights. Fewer patients exposed to only one biologic achieved PASI 75 at weeks 4, 20, 28, and 36 [odds ratio (OR) = 0.08 (95% CI, 0.01–0.48), 0.21 (95% CI, 0.05–0.74), 0.04 (95% CI, 0.00–0.35), and 0.07 (95% CI, 0.00–0.68), respectively] than biologic-naïve patients. Patients previously treated with more than one biologic were less likely to achieve PASI 75 at weeks 12, 20, 28, and 36 [OR = 0.05 (95% CI, 0.01–0.22), 0.03 (95% CI, 0.01–0.16), 0.00 (95% CI, 0.00–0.03), and 0.00 (95% CI, 0.00–0.044), respectively] than biologic-naïve patients. Patients with previous anti-interleukin (IL)-17 exposure, rather than tumour necrosis factor-α and IL-12/23 inhibitors, had lower PASI improvements to guselkumab than biologic-naïve patients at weeks 12, 20, and 28 [OR = 0.19 (95% CI, 0.03–0.90), 0.10 (95% CI, 0.02–0.55), and 0.03 (95% CI, 0.00–0.29), respectively]. Conclusions: The effectiveness of guselkumab was compromised in a real-world setting. Delayed onset of therapeutic response was noted in heavier patients. Biologic exposure, the number of previously used biologics, and previous exposure to IL-17 inhibitors were clinical predictors of a reduced response to guselkumab. Physicians may share this information with patients to make treatment decisions.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“… 15 , 16 , 19 , 21 Predictors of a PASI response to guselkumab available from real-life studies are relatively lacking and inconsistent. 15 – 18 …”

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

Hung

Lin

Chiu

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data

et al. 2023

View full text Add to dashboard Cite

Nowadays, the biological equipment available for the treatment of moderate-to-severe psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the management of moderate-to-severe psoriasis. Their efficacy and safety have been assessed through two major sources: clinical trials (CTs) and real-world experiences data (RWE). Notably, the two sources differ from one another, but together, they complement information and current knowledge on both efficacy and safety of biological therapy. We carry out a review on CTs and RWE reports on the latest group of biological approved for moderate-to-severe psoriasis: anti-IL23 (guselkumab, risankizumab, and tildrakizumab).

show abstract

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study

Gargiulo

Ibba

Pavia

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Risankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It is approved for treatment of moderate-to-severe plaque psoriasis. We conducted a 52-week monocentric retrospective study to evaluate the effectiveness and safety of risankizumab in a real-life setting. Methods Our study included 131 adults with moderate-to-severe plaque psoriasis all treated with risankizumab for at least 52 weeks. Patient characteristics and PASI (Psoriasis Area and Severity Index) at each visit were recorded. The percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI with respect to baseline were registered. Results At week 52, 93.9%, 78.6%, and 61.1% of patients achieved PASI 75/90/100, respectively. An absolute PASI ≤ 2 was reached by 90.8% at week 52. The higher body mass index and the presence of cardio-metabolic comorbidities did not interfere with the odds of reaching PASI 75/90/100 at each time-point. At week 52, comparable percentages of patients achieved PASI 100, regardless of the involvement of difficult-to-treat-areas. No significant safety findings were recorded and none of the patients had to interrupt the treatment because of adverse events. Conclusions Our findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide “real-life” cohort of patients with psoriasis.

show abstract

Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience

Cited by 31 publications

References 12 publications

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data

Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study

Contact Info

Product

Resources

About